Skip to content
2000
Volume 15, Issue 3
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Prostate cancer is one of the most prevalent cancer types in men worldwide. With the progression of the disease to independent stimulation by androgen hormones, it becomes more difficult to control its progress. In addition, several studies have shown that chronic inflammation is directly related to the onset and progression of this cancer. For many decades, conventional chemotherapeutic drugs have not made significant progress in the treatment of prostate cancer. However, the discovery of docetaxel yielded the first satisfactory responses of increased survival of patients. In addition, alternative therapies using biomolecules derived from secondary metabolites of natural products are promising in the search for new treatments. Despite the advances in the treatment of this disease in the last two decades, the results are still insufficient and conventional therapies do not present the expected results they once promised. Thus, a revision and (re)establishment of prostate cancer therapeutic strategies are necessary. In this review, we also approach suggested treatments for molecular biomarkers in advanced prostate cancer.

Loading

Article metrics loading...

/content/journals/cdth/10.2174/1574885514666190917150635
2020-06-01
2025-05-23
Loading full text...

Full text loading...

/content/journals/cdth/10.2174/1574885514666190917150635
Loading

  • Article Type:
    Review Article
Keyword(s): biomarkers; docetaxel; inflammation; natural products; Prostate cancer; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test